Outcomes following splenectomy in patients with myeloid neoplasms

Journal of Surgical Oncology

Volumn 111, Issue 4, 2015, Pages 389-395

  Rialon, Kristy L ^a   Speicher, Paul J ^a   Ceppa, Eugene P ^b   Rendell, Victoria R ^a   Vaslef, Steven N ^a   Beaven, Anne ^a   Tyler, Douglas S ^a   Blazer, Dan G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Hypersplenism; Myelofibrosis; Myeloproliferative neoplasm; Splenomegaly

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW TUMOR; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CYTOPENIA; FEMALE; HUMAN; HYPOALBUMINEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SPLENECTOMY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; LEUKEMIA, MYELOID; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATION; REOPERATION;

AGED; ANEMIA; FEMALE; HUMANS; HYPOALBUMINEMIA; LEUKEMIA, MYELOID; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETROSPECTIVE STUDIES; SPLENECTOMY;

EID: 84923779882     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23846     Document Type: Article

References (42)

1. Vannucchi AM, Guglielmelli P, Tefferi A: Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009; 59: 171-191.
2. Tefferi A, Thiele J, Orazi A, et al.: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
3. Hickling RA: Splenectomy in myeloid metaplasia. Q J Med 1937; 30: 253.
4. Mesa RA, Nagorney DS, Schwager S, et al.: Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361-370.
5. Silverstein MN, ReMine WH: Sex, splenectomy, and myeloid metaplasia. JAMA 1974; 227: 424-426.
6. Tefferi A, Mesa RA, Nagorney DM, et al.: Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000; 95: 2226-2233.
7. Guardiola P, Anderson JE, Bandini G, et al.: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831-2838.
8. Deeg HJ, Gooley TA, Flowers ME, et al.: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912-3918.
9. Lafaye F, Rain JD, Clot P, et al.: Risks and benefits of splenectomy in myelofibrosis: An analysis of 39 cases. Nouv Rev Fr Hematol 1994; 36: 359-362.
10. Barosi G, Ambrosetti A, Buratti A, et al.: Splenectomy for patients with myelofibrosis with myeloid metaplasia: Pretreatment variables and outcome prediction. Leukemia 1993; 7: 200-206.
11. Taner T, Nagorney DM, Tefferi A, et al.: Splenectomy for massive splenomegaly: Long-term results and risks for mortality. Ann Surg 2013; 258: 1034-1039.
12. Brenner B, Nagler A, Tatarsky I, et al.: Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases. Arch Intern Med 1988; 148: 2501-2505.
13. Silverstein MN, ReMine WH: Splenectomy in myeloid metaplasia. Blood 1979; 53: 515-518.
14. Bickenbach KA, Gonen M, Labow DM, et al.: Indications for and efficacy of splenectomy for haematological disorders. Br J Surg 2013; 100: 794-800.
15. Dindo D, Demartines N, Clavien PA: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 250-213.
16. Swerdlow SH, Campo E, Harris NL, et al.: WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC 2008.
17. Benbassat J, Gilon D, Penchas S: The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol 1990; 33: 128-135.
18. Horowitz J, Smith JL, Weber TK, et al.: Postoperative complications after splenectomy for hematologic malignancies. Ann Surg 1996; 223: 290-296.
19. Dameshek HL, Ellis LD: Hematologic indications for splenectomy. Surg Clin North Am 1975; 55: 253-275.
20. Dawson AA, Jones PF, King DJ: Splenectomy in the management of haematological disease. Br J Surg 1987; 74: 353-357.
21. Ellison EC, Fabri PJ: Complications of splenectomy. Etiology, prevention, and management. Surg Clin North Am 1983; 63: 1313-1330.
22. Hays DM, Ternberg JL, Chen TT, et al.: Complications related to 234 staging laparotomies performed in the Intergroup Hodgkin's Disease in Childhood study. Surgery 1984; 96: 471-478.
23. Johansson T, Bostrom H, Sjodahl R, Ihse I: Splenectomy for haematological diseases. Acta Chir Scan 1990; 156: 83-86.
24. Laborde RR, Patnaik MM, Lasho TL, et al.: SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia (CMML): Independent prognostic impact in CMML. Leukemia 2013; 5.
25. Laws HL, Burlingame MW, Carpenter JT, et al.: Splenectomy for hematologic disease. Surg Gynecol Obstet 1979; 149: 509-512.
26. Malmaeus J, Akre T, Adami HO, Hagberg H: Early postoperative course following elective splenectomy in haematological diseases: A high complication rate in patients with myeloproliferative disorders. Br J Surg 1986; 73: 720-723.
27. Mitchell A, Morris PJ: Splenectomy for malignant lymphomas. World J Surg 1985; 9: 444-448.
28. Musser G, Lazar G, Hocking W, et al.: Splenectomy for hematologic disease. The UCLA experience with 306 patients. Ann Surg 1984; 200: 40-45.
29. Sandusky WR, Leavell BS, Benjamin BI: Splenectomy: Indications and results in hematologic disorders. Ann Surg 1964; 159: 695-710.
30. Wilhelm MC, Jones RE, McGehee R, et al.: Splenectomy in hematologic disorders. The ever-changing indications. Ann Surg 1988; 207: 581-589.
31. Adler S, Stutzman L, Sokal J, et al.: Splenectomy for hematologic depression in lymphocytic lymphoma and leukemia. Cancer 1975; 35: 521-528.
32. Barosi G, Ambrosetti A, Centra A, et al.: Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on myeloid with myeloid metaplasia. Blood 1998; 91: 3630-3636.
33. Dupriez B, Demory JL, Lai JL, et al.: Prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1989; 73: 136-137.
34. Barugola G, Cavallini A, Lipari G, et al.: The role of splenectomy in myelofibrosis with myeloid metaplasia. Minerva Chir 2010; 65: 619-625.
35. Akpek G, McAneny D, Weintraub L: Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: A retrospective analysis of 26 cases. J Surg Oncol 2001; 77: 42-48.
36. Jarvinen H, Kivilaakso E, Ikkala E, et al.: Splenectomy for myelofibrosis. Ann Clin Res 1982; 14: 66-71.
37. Feldman LS, Demyttenaere SV, Polyhronopoulos GN, et al.: Refining the selection criteria for laparoscopic versus open splenectomy for splenomegaly. J Laparoendosc Adv Surg Tech A 2008; 18: 13-19.
38. Casaccia M, Torelli P, Pasa A, et al.: Putative predictive parameters for the outcome of laparoscopic splenectomy: A multicenter analysis performed on the Italian Registry of Laparoscopic Surgery of the Spleen. Ann Surg 2010; 251: 287-291.
39. Li Z, Gooley T, Applebaum FR, et al.: Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 2001; 97: 2180-2181.
40. Rondelli D, Barosi G, Bacigalupo A, et al.: Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate-or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-4119.
41. Michallet M, Corront B, Bosson JL, et al.: Role of splenectomy in incidence and severity of acute graft-versus-host disease: A multicenter study of 157 patients. Bone Marrow Transpl 1991; 8: 13-17.
42. Baughan AS, Worsley AM, McCarthy DM, et al.: Haematological reconstitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocytic leukaemia: The influence of previous splenectomy. Br J Haematol 1984; 56: 445-454.